A multicentre, prospective, randomised, double-blind, placebo-controlled, international study to assess the effects of 2 g per day of strontium ranelate versus placebo on the time to fracture healing in osteoporotic men and women.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 04 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Strontium ranelate (Primary)
Indications Male osteoporosis; Postmenopausal osteoporosis
Focus Registrational; Therapeutic Use
Acronyms Fracture healing
Sponsors IRIS; Servier

Most Recent Events

29 Mar 2012 This trial has been completed in Germany and Hungary.
22 Feb 2012 This trial has been completed in Czech Republic as reported by European Clinical Trials Database record.
11 May 2011 Planned end date changed from 31 Jul 2011 to 31 Mar 2012 as reported by ISRCTN: Current Controlled Trials.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight